#United States #healthcare #Burlington #Investor Day #Labcorp

Labcorp's 2026 Investor Day: A Vision for the Future

On September 10, 2026, Labcorp (NYSE: LH), a leader in innovative laboratory services, hosted its 2026 Investor Day, where it presented key strategic priorities and its long-term financial outlook to investors. The event emphasized Labcorp's commitment to driving growth through cutting-edge science, technology, and operational excellence at the intersection of diagnostics and biopharma.

Growth Strategy and Market Position

Labcorp’s CEO, Adam Schechter, articulated that the company is more relevant than ever in today’s evolving healthcare landscape, which is defined by scientific innovations and a focus on personalized medicine. He emphasized that Labcorp's robust growth strategy positions the company for above-market performance, expecting a compound annual growth rate (CAGR) of 5% to 8% in revenue and an adjusted earnings per share (EPS) growth of 8.5% to 11.5% through 2029.

During the Investor Day, Labcorp showcased four major strategic priorities aimed at fostering growth and reinforcing its leadership in the healthcare ecosystem:

1. Innovation in Specialty Testing: Labcorp aims to lead in specialty testing with ongoing advancements in areas like oncology, neurology, and women's health. This commitment ensures that Labcorp remains at the forefront of medical diagnostics.
2. Partner of Choice: The company plans to enhance partnerships with health systems and pharmaceutical companies, leveraging its scientific expertise and operational capabilities to provide superior services.
3. Personalized Health Solutions: Using data and insights, Labcorp intends to drive personalized healthcare solutions that assist in therapy development and selection, ultimately delivering tailored experiences to patients.
4. Advanced Technology Utilization: The integration of modern technologies, including artificial intelligence and robotics, is a critical component of Labcorp's future, supporting operational efficiencies and improving patient outcomes.

Long-Term Financial Outlook

In reaffirming its guidance for 2026, Labcorp provided a comprehensive financial outlook through 2029, expressing confidence in sustained revenue growth and improving margins. The key financial targets include:

• - An expected CAGR of revenue growth between 5% and 8%.
• - A projected increase in adjusted operating margin by 75 to 150 basis points by the end of 2029.
• - A CAGR for adjusted EPS growth between 8.5% and 11.5%.
• - Anticipated growth in free cash flow that is consistent with adjusted earnings growth, reflecting a disciplined approach to capital allocation.

Julia Wang, Labcorp's Executive Vice President and CFO, reinforced the importance of a well-structured value creation framework. This framework is designed to convert growth into tangible earnings and shareholder returns, supported by a history of delivering on financial commitments.

The webcast for this event is available for those who missed it, complete with supporting materials, ensuring transparency and accessibility for all investors.

Commitment to Innovation and Value Creation

Labcorp's strong track record in delivering innovative solutions fuels its ability to meet evolving healthcare demands. The company’s dedication to advancing laboratory services means it has supported over 85% of new FDA-approved therapeutic products in 2025 and conducted more than 750 million tests globally.

In summary, Labcorp's 2026 Investor Day revealed a comprehensive look at how the company plans to position itself at the forefront of the healthcare industry. Its strategic priorities are firmly rooted in innovation and partnership, ensuring long-term value creation for its clients, shareholders, and patients alike. As the healthcare landscape continues to evolve, Labcorp stands ready to adapt and lead in this dynamic market.